- AI
- Molecular Imaging
- CT
- X-Ray
- Ultrasound
- MRI
- Facility Management
- Mammography
Elbit studies corporate spin-off plan
Elbit announced Dec. 7 that its board of directors in Haifa hasinstructed management to explore the possibility of spinning offits healthcare, defense and commercial business interests intoseparately run companies. Under the proposal, Elscint and the
Elbit announced Dec. 7 that its board of directors in Haifa hasinstructed management to explore the possibility of spinning offits healthcare, defense and commercial business interests intoseparately run companies.
Under the proposal, Elscint and the ultrasound assets of Diasonicsin Santa Clara, CA, Vingmed Sound A/S of Norway and Sonotron HoldingAG of Switzerland would be merged into a single company. In combination,these businesses are expected to produce more than $500 millionin sales in 1995.
In a separate development, Elbit took a step toward consolidatingits ultrasound operations in November by purchasing the ultrasound-relatedassets of Elscintec, a manufacturing and R&D group owned byElscint, a subsidiary of Elbit. The deal is worth at least $14million, according to Elbit.
Can Portable Dual-Energy X-Ray be a Viable Alternative to CT in the ICU?
September 13th 2024The use of a portable dual-energy X-ray detector in the ICU at one community hospital reportedly facilitated a 37.5 percent decrease in chest CT exams in comparison to the previous three months, according to research presented at the American Society of Emergency Radiology (ASER) meeting in Washington, D.C.
New Meta-Analysis Examines MRI Assessment for Treatment of Esophageal Cancer
September 12th 2024Diffusion-weighted MRI provided pooled sensitivity and specificity rates of 82 percent and 81 percent respectively for gauging patient response to concurrent chemoradiotherapy for esophageal cancer, according to new meta-analysis.
Study for Emerging PET/CT Agent Reveals ‘New Standard’ for Detecting Clear Cell Renal Cell Carcinoma
September 11th 2024Results from a multicenter phase 3 trial showed that the PET/CT imaging agent (89Zr)Zr-girentuximab had an 85.5 percent mean sensitivity rate for the diagnosis of clear cell renal cell carcinoma.
Can Radiomics and Autoencoders Enhance Real-Time Ultrasound Detection of Breast Cancer?
September 10th 2024Developed with breast ultrasound data from nearly 1,200 women, a model with mixed radiomic and autoencoder features had a 90 percent AUC for diagnosing breast cancer, according to new research.
